Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2009-01-20 / J. Dermatol. Sci. 2009 Apr;54(1):31-7Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2009-01-12 / J. Clin. Oncol. 2009 Feb;27(6):945-52Mechanisms of murine dendritic cell antitumor dysfunction in aging
/in International Publications, Malignant Melanoma, NSCLC /von 2008-12-13 / Cancer Immunol. Immunother. 2009 Dec;58(12):1935-9Dendritic cells in the skin–potential use for melanoma treatment
/in International Publications, Malignant Melanoma /von 2008-11-27 / Pigment Cell Melanoma Res 2009 Feb;22(1):30-41Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells
/in International Publications, Malignant Melanoma /von 2008-11-15 / Cancer Res. 2008 Nov;68(22):9441-50Tumor infection by oncolytic reovirus primes adaptive antitumor immunity
/in International Publications, Malignant Melanoma /von 2008-11-15 / Clin. Cancer Res. 2008 Nov;14(22):7358-66[Activation of anti-tumor cytotoxic T lymphocytes by fusion of human dendritic cells and melanoma cells]
/in International Publications, Malignant Melanoma /von 2008-11-01 / Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008 Nov;33(11):1012-8The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells
/in International Publications, Malignant Melanoma /von 2008-10-23 / Exp. Dermatol. 2009 Apr;18(4):396-403Dendritic cells pulsed with keyhole limpet hemocyanin and cryopreserved maintain anti-tumor activity in a murine melanoma model
/in International Publications, Malignant Melanoma /von 2008-10-08 / Clin. Immunol. 2008 Dec;129(3):482-91
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de